PTC Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $164,677 | $211,007 | $178,875 | $1,176,096 |
Gross Profit | 148,378 | 95,068 | 167,455 | 1,163,234 |
EBITDA | -70,993 | 20,627 | -33,111 | 971,141 |
EBIT | -83,895 | 9,518 | -40,694 | 963,920 |
Net Income | -134,965 | 15,896 | -64,849 | 866,562 |
Net Change In Cash | 164,677 | 211,007 | 178,875 | 1,176,096 |
Free Cash Flow | -36,647 | -69,746 | -62,327 | 867,571 |
Cash | 984,648 | 672,617 | 1,017,386 | 1,480,231 |
Basic Shares | 80,689 | 87,115 | 78,151 | 86,385 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $1,730,655 | $806,780 | $937,822 | $698,801 |
Gross Profit | 1,658,900 | 749,382 | 872,336 | 654,123 |
EBITDA | 887,664 | -120,463 | -330,340 | -367,780 |
EBIT | 848,849 | -196,126 | -566,930 | -496,616 |
Net Income | 682,644 | -363,295 | -626,604 | -559,017 |
Net Change In Cash | 1,730,655 | 806,780 | 937,822 | 698,801 |
Cost of Revenue | 101,479 | |||
Free Cash Flow | 702,336 | -181,937 | -279,037 | -509,114 |
Cash | 984,648 | 779,709 | 594,001 | 279,834 |
Basic Shares | 88,311 | 76,845 | 74,838 | 71,728 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$1.79 |
2025-09-30 | $0.20 |
2025-06-30 | -$0.83 |
